Table 1.

Efficacy prediction for the virtual patient cohort generated based on calibrated parameter distribution

Variable	Nab-paclitaxel	Atezolizumab/nab-paclitaxel
Response
Number of virtual patients	450	450
Objective response
No. of patients (median)	209	266
% of patient (95 bootstrap percentile)	46.4 (41.0–52.0)	59.1 (53.2–64.7)
Complete response
No. of patients (median)	9	11
% of patient (95 bootstrap percentile)	2.0 (0.7–3.9)	2.4 (0.9–4.4)
Partial response
No. of patients (median)	200	255
% of patient (95 bootstrap percentile)	44.4 (38.9–50.7)	56.7 (50.6–62.2)
Stable disease
No. of patients (median)	138	106
% of patient (95 bootstrap percentile)	30.7 (25.7–36.2)	23.6 (18.7–28.2)
Progressive disease
No. of patients (median)	103	78
% of patient (95 bootstrap percentile)	22.9 (18.2–27.6)	17.3 (13.1–21.6)
Duration of response
Number of virtual patients	209	266
Median duration of response in months (95 bootstrap percentile)	5.6 (5.6–7.5)	7.5 (5.6–9.3)
No. of virtual patients with ongoing response after 400 days of treatment in model simulations (%)	69 (33.2)	87 (32.7)

Bootstrap median and CIs are reported.